Ensysce Biosciences Announces Acquisition of CY Biopharma and Concurrent Private Financing of up to $77 Million

Dr William Schmidt discusses the ideal analgesic profile – from the IASP World Congress 2024.

Main Logo

Biotech company committed to stemming the prescription drug abuse epidemic.

Our proprietary prodrug technologies are designed to improve the care of patients with severe pain while reducing the human and economic costs associated with prescription drug abuse.

About Us

Our philosophy
The Industry and Us

Our strategy

Our Technology
Key Applications
Clinical Programs
Preclinical Programs
Pipeline
Our Partnerships

Our Team

Executive Management
Board of Directors
Clinical Advisory Board

Media / Science Center

Contact Us

Investors

Follow Ensysce on social media:

/company/Ensyscebio
@Ensyscebio
/Ensyscebio